hVIVO successfully completes RSV challenge study in Older Adults

hVIVO signs new contracts with global biopharmaceutical firm

hVIVO signs new contracts with global biopharmaceutical firm ▪ Contracted for two respiratory syncytial virus (RSV) human challenge studies▪ Studies projected to deliver a total of c.£9m in revenue from Q4’18 through to end of2019▪ Builds on recently announced £11.9m...
hVIVO successfully completes RSV challenge study in Older Adults

Queen Mary joins London cancer research powerhouse

Queen Mary joins London cancer research powerhouse The city of London will be transformed into a world leading hub for cancer biotherapeutics research and treatment, with a new £14 million investment from Cancer Research UK, announced today. The new Cancer Research...
hVIVO Landmark Asthma Stratification Initiative Underway

hVIVO Landmark Asthma Stratification Initiative Underway

hVIVO Landmark Asthma Stratification Initiative Underway hVIVO plc (AIM: HVO), the pioneer of human disease models, is delighted to announce that the Company’s landmark asthma stratification initiative is now underway, with the first volunteer inoculated with human...
Retroscreen Virology Changes its Name to hVIVO

Retroscreen Virology Changes its Name to hVIVO

Retroscreen Virology Changes its Name to hVIVO Retroscreen Virology is proud to announce corporate name change to hVIVO to reflect pioneering efforts in human disease models. Revolutionising drug development through human studies Retroscreen Virology, a leading life...
Previous Next
Close
Test Caption
Test Description goes like this